As more hospitals begin to incorporate the da Vinci surgical robot system into their increasingly high-tech array of medical tools, they are finding the devices under heightened U.S. Food and Drug Administration scrutiny. The Rottenstein Law Group LLP comments on recent reports about problems with the da Vinci surgical robot failing during procedures.
Earlier this month, the FDA announced that da Vinci maker Intuitive Surgical had notified its customers of a problem involving the device stalling during surgical procedures, causing some problematic malfunctioning, according to a Dec. 4 Bloomberg story. Friction in one of the device’s arms would cause the tools to stall, the story said. In the first ten months of 2013, the FDA received nearly 4,000 adverse event reports, ranging from claims of injury to death, according to a Nov. 11 Businessweek article.
“There is a well-documented and growing body of professional research to support the claims we hear daily from people pursuing da Vinci lawsuits,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP, which represents clients in da Vinci surgical robot lawsuits. “This is not a guarantee that all of this evidence is admissible in court, but there is the potential for this data to aid in advancing the claims of those who believe they have suffered from the serious alleged side effects of robotic surgery.”
The da Vinci surgical robot system typically features four mechanical arms with precision surgical tools and a camera, designed to allow a surgeon to perform procedures such as prostate removals and hysterectomies less invasively than in the past. However, the robot system has been found to cause potentially dangerous side effects, such as internal burns, nerve damage and lacerations, according to Bloomberg.